Gastrointestinal

This article is based on the recent scientific review “Inflammatory bowel disease: recent developments,”  published in 2024 in the journal Archives of Disease in Childhood  by Professor James John Ashton and Professor R. Mark Beattie. The authors are leading experts in pediatric gastroenterology and genetics affiliated with Southampton Children’s Hospital and the University of Southampton, United Kingdom. In their review, they examine the latest advancements in the diagnosis,

This article summarizes the most important information that every patient with inflammatory bowel disease (IBD)—including ulcerative colitis and Crohn’s disease—should know about their condition and its treatment. All answers are entirely based on the scientific review “Treatment of Inflammatory Bowel Disease: A Comprehensive Review,”  published in December 2021 in the journal Frontiers in Medicine . The authors of the review are Zhaobei Cai (Department of General Surgery, Se

This article summarizes the most important and up-to-date information about inflammatory bowel disease (IBD) in older adult patients, based entirely on the systematic review “Therapeutic Needs of Older Adults with Inflammatory Bowel Disease (IBD): A Systematic Review,” published in 2024 in Gastroenterology Insights  (Davis et al., 2024). The authors of this comprehensive analysis—Suja P. Davis, Rachel McInerney, Stephanie Fisher, and Bethany Lynn Davis—are healthcare speciali

The information in this article is based on the latest scientific review “Key Interleukins in Inflammatory Bowel Disease – A Review of Recent Studies,”  published in 2025 in the International Journal of Molecular Sciences . The study was led by Professor David Aebisher (Department of Photomedicine and Physical Chemistry, Medical College of The Rzeszów University, Poland). Co-authors of the publication include Dorota Bartusik-Aebisher, Agnieszka Przygórzewska, and Paweł Woźnic

This article is based entirely on the most recent publication “Challenges in IBD Research 2024: Precision Medicine,”  published in the prestigious journal Inflammatory Bowel Diseases  in 2024. The authors are a multidisciplinary team of leading international researchers, clinicians, and patient organization representatives, including pediatricians, gastroenterologists, biologists, medical technology experts, and patient-experts from universities and research institutions acro

The information in this article is based on the most recent and widely recognized treatment guideline for Crohn’s disease, published in the Journal of Crohn’s and Colitis  in 2020 under the title “ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment.”  The guideline was developed by 48 leading gastroenterologists, surgeons, and researchers from across Europe, selected by the European Crohn’s and Colitis Organisation (ECCO) based on their expertise, academic a

This article is based on the most recent clinical guidelines from the American Gastroenterological Association (AGA), published in the journal Gastroenterology  in 2020: “AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis”  (Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, on behalf of the AGA Institute Clinical Guidelines Committee). The team behind this document includes leading gastroenterologists, clinica

Inflammatory Bowel Disease (IBD) encompasses two major chronic conditions—Crohn’s disease and ulcerative colitis. These are autoimmune, multisystem disorders that primarily affect the digestive system, but they often impact other organs as well. Crohn’s disease can affect any part of the gastrointestinal (GI) tract—from the mouth to the anus—and is characterized by “skip lesions” (segmental inflammatory activity) and involvement of all layers of the intestinal wall. In contra

Irritable bowel syndrome (IBS) is one of the most common, yet often misunderstood, functional gastrointestinal disorders. Its symptoms can range from mild to disabling and frequently lead to a significant reduction in the quality of life for those affected. In an effort to provide the best possible knowledge and practical guidance for diagnosis and treatment, a large team of leading Indian gastroenterologists, researchers, and clinicians collaborated to create one of the most

The information in this article is entirely based on the comprehensive scientific review "Intestinal Microbiota And Diet in IBS: Causes, Consequences, or Epiphenomena?"  published in the prestigious journal The American Journal of Gastroenterology  (2015, Volume 110, pp. 278–287), DOI: 10.1038/ajg.2014.427. The authors include renowned scientists and clinicians from various countries and fields, such as Mirjana Rajilić-Stojanović (PhD, University of Belgrade), Daisy M. Jonker

The information in this article has been carefully selected and summarized based on the most up-to-date scientific publication, "Causative Factors, Clinical Manifestations, and Therapeutic Strategies for Irritable Bowel Syndrome"  (Cureus, 2024), by Khushi Anand and Mahalaqua Nazli Khatib—researchers and practicing physicians from Jawaharlal Nehru Medical College at the Datta Meghe Institute of Higher Education and Research (India). Dr. Anand and Dr. Khatib are experts in int

Irritable Bowel Syndrome (IBS) is one of the most common functional gastrointestinal disorders, affecting millions of people worldwide and significantly impacting patients’ quality of life. In search of the most up-to-date and evidence-based answers, this article draws entirely from the review “Diagnosis and Treatment of Irritable Bowel Syndrome: A Review” , published in 2020 in one of the most respected medical journals— JAMA (Journal of the American Medical Association) . T

This article presents a synthesized and patient-friendly overview, based entirely on the peer-reviewed scientific review "Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis,"  published in Frontiers in Cellular and Infection Microbiology  in September 2020. The review was authored by a team of scientists and researchers from renowned institutions in New Zealand and Australia, including Massey University, t

Irritable Bowel Syndrome (IBS) is a common and socially significant condition that affects millions of people worldwide, disrupting daily routines, eating habits, and overall quality of life. Despite medical advancements, treating IBS remains a challenge, as standard pharmaceutical approaches often have limited effectiveness or come with unwanted side effects. This article is entirely based on information from the peer-reviewed scientific publication "GOS to Reduce Symptom Se

Over the past decade, the role of gut microbiota in irritable bowel syndrome (IBS) has sparked growing interest among both scientists and patients. To bring you the most up-to-date and evidence-based information, this article summarizes key findings from the peer-reviewed review "The gut microbiome and irritable bowel syndrome"  (2018), published in F1000Research . The article was written by Dr. Stacy Menees and Professor Dr. William Chey—leading American gastroenterologists

Irritable Bowel Syndrome (IBS) is a chronic functional disorder of the gastrointestinal (GI) tract that affects millions of people worldwide. It often disrupts daily life, social interactions, and psychological well-being. In response to the need for up-to-date, evidence-based recommendations, leading Korean gastroenterologists, psychologists, and public health experts—brought together by the Korean Society of Neurogastroenterology and Motility—developed consensus clinical gu

This article is based on the 2020 review by Prof. Dr. Michael Camilleri, one of the world’s leading experts in gastroenterology and head of the Center for Neurogastroenterology and Hepatology at the Mayo Clinic, USA. His publication “Irritable Bowel Syndrome: Straightening the road from the Rome criteria”  offers a comprehensive analysis of the development, challenges, and recent scientific advances related to Irritable Bowel Syndrome (IBS). Prof. Camilleri summarizes the exp

The information presented in the following Q&A is carefully selected and synthesized from the peer-reviewed scientific review “Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites,”  published in Nutrients  in January 2025 (García Mansilla et al., 2025). The review was authored by a team of leading researchers and clinicians from several Spanish academic and biomedical institutions: the University of

This article presents the most important, up-to-date, and evidence-based information about Irritable Bowel Syndrome (IBS), intended especially for patients and their loved ones. All advice, facts, and recommendations are based on the consensus Guidelines on the management of irritable bowel syndrome , published in the prestigious Gastroenterology Review  in 2018. The team of authors includes leading researchers and gastroenterologists from top university and clinical centers

In this article, we explore important and often overlooked aspects of the overlap between irritable bowel syndrome (IBS) and vulvodynia. Our discussion is based entirely on the systematic review titled “Investigating the overlapping presentation of irritable bowel syndrome and vulvodynia: A systematic review of the evidence and mechanisms”  by authors S. Perelmuter (Weill Cornell Medicine), K. Maliszewski (Des Moines University), and A. Soogoor (William Carey University Colle